Electromed, Inc. (ELMD) reported its fiscal 2026 second‑quarter results, posting revenue of $18.9 million—an increase of 16.3 % from $16.3 million in the same period last year—and earnings per share of $0.32, surpassing consensus estimates of $0.25–$0.273.
Revenue growth was driven almost entirely by the company’s direct home‑care channel, which generated $17.3 million—an 18.4 % rise—thanks to a larger sales force and higher per‑representative sales. The remaining $1.6 million came from other segments, including hospital and distributor sales, which remained flat.
Gross profit reached $14.8 million, or 78.4 % of net revenues, reflecting strong pricing power and disciplined cost control. Operating income climbed to $3.6 million, or 19.2 % of net revenues, an improvement over the 15.6 % margin reported in Q2 FY2025, driven by higher revenue mix and scale. Net income of $2.8 million underscored the company’s ability to translate top‑line growth into profitability.
EPS of $0.32 beat analyst expectations by $0.05–$0.07, a 19–28 % overrun, as the company’s operating leverage and cost discipline offset the modest increase in operating expenses. The 45 % YoY rise in EPS from $0.22 in Q2 FY2025 highlights the company’s accelerating profitability.
CEO Jim Cunniff said the results reflected the success of the company’s “Triple Down on Bronchiectasis” marketing campaign, which has increased physician and patient awareness of the SmartVest® system. He added that Electromed remains focused on expanding its underpenetrated bronchiectasis market while balancing investments with shareholder returns through ongoing share repurchases.
Investors reacted positively to the earnings beat and margin expansion, citing the company’s disciplined execution and strong market position in airway clearance technologies. Electromed’s cash balance of $13.8 million and absence of debt provide a solid foundation for continued growth and shareholder value creation.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.